Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Diabetic Retinopathy

ClinicalTrials.gov lists 681 trials for Diabetic Retinopathy or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 25.

MeSH D003930 Eye Diseases C11 C14 C19
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 73 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 59 Phase 4 Phase 4 50 Not applicable Not applicable 183 Observational Observational 250 Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 73 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 59 Phase 4 Phase 4 50 Not applicable Not applicable 183 Observational Observational 250

Trials per phase (log scale)

681 of the 681 trials are tagged with Diabetic Retinopathy itself; the rest are tagged with a narrower condition beneath it.

Get the Diabetic Retinopathy report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Diabetic Retinopathy trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 49

1992: 2 trials (Observational 2) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Observational 1) 1997: 1 trials (Observational 1) 1998: 2 trials (Observational 1, Phase 3 1) 1999: 2 trials (Phase 3 2) 2000: 3 trials (Observational 2, Phase 3 1) 2001: 5 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 1) 2002: 2 trials (Observational 1, Phase 2 1) 2003: 4 trials (Phase 3 1, Phase 2 1, Phase 1 2) 2004: 5 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 1) 2005: 12 trials (Observational 2, Not applicable 1, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1 1) 2006: 24 trials (Observational 4, Not applicable 4, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2007: 22 trials (Observational 7, Not applicable 4, Phase 4 2, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 3) 2008: 28 trials (Observational 6, Not applicable 4, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1/2 3, Phase 1 4) 2009: 20 trials (Observational 4, Not applicable 7, Phase 4 1, Phase 3 3, Phase 2 4, Phase 1 1) 2010: 13 trials (Observational 2, Not applicable 5, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1 1) 2011: 19 trials (Observational 8, Phase 4 4, Phase 3 3, Phase 2 3, Phase 1/2 1) 2012: 26 trials (Observational 11, Not applicable 7, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2013: 17 trials (Observational 5, Not applicable 4, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1) 2014: 22 trials (Observational 11, Not applicable 10, Phase 2/3 1) 2015: 25 trials (Observational 8, Not applicable 8, Phase 4 3, Phase 2 3, Phase 1 3) 2016: 31 trials (Observational 11, Not applicable 11, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2017: 23 trials (Observational 15, Not applicable 2, Phase 4 3, Phase 2 3) 2018: 45 trials (Observational 24, Not applicable 9, Phase 4 2, Phase 3 6, Phase 2 2, Phase 1 2) 2019: 36 trials (Observational 13, Not applicable 14, Phase 4 3, Phase 3 2, Phase 2 1, Phase 1/2 2, Phase 1 1) 2020: 32 trials (Observational 6, Not applicable 8, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 2) 2021: 44 trials (Observational 14, Not applicable 11, Phase 4 5, Phase 3 3, Phase 2/3 2, Phase 2 8, Phase 1/2 1) 2022: 49 trials (Observational 25, Not applicable 14, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1 4) 2023: 30 trials (Observational 13, Not applicable 12, Phase 2 5) 2024: 39 trials (Observational 14, Not applicable 16, Phase 4 3, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2025: 46 trials (Observational 27, Not applicable 15, Phase 4 1, Phase 2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 41
2025 46
2024 39
2023 30
2022 49
2021 44
2020 32
2019 36
2018 45
2017 23

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 51 trials starting in 2026 and about 46 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 56 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 390 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Diabetic Retinopathy trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 40
Phase 1/2 15
Phase 2 73
Phase 2/3 11
Phase 3 59
Phase 4 50
Not applicable 183
Observational 250

How many Diabetic Retinopathy trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 31
Recruiting 72
Enrolling by invitation 8
Active, not recruiting 26
Completed 358

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Diabetic Retinopathy trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Eye Institute (NEI) 25
Novartis Pharmaceuticals 11
Bayer 6
Hospital Juarez de Mexico 6

Which drugs are being tested for Diabetic Retinopathy? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Ruboxistaurin 3
rHuPH20 3
KSI-301 3

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
2.0 aflibercept 37
ranibizumab PRN 31
Bevacizumab 1 22
Triamcinolone Acetonide alone 10
SHAM injection 9

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Diabetic Retinopathy trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Cardiac failure congestive 167 14
Coronary artery disease 147 20
Pneumonia 119 22
Cellulitis 118 20
Cerebrovascular accident 112 19

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Diabetic Retinopathy? (1,480)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema. BMJ open ophthalmology 2026 Yes
Assessment of Correlation Between Diabetic Retinopathy and Metabolic Biomarkers Using Artificial Intelligence. Journal of diabetes research 2026 Yes
One-Year Progression of Capillary Nonperfusion in Nonproliferative Diabetic Retinopathy Using Noninvasive Imaging: The CHART Study. Translational vision science & technology 2026 Yes
Blood omega-3 biomarkers, diabetic retinopathy and retinal vessel status in patients with type 1 diabetes. Eye (London, England) 2025 Yes
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. JAMA ophthalmology 2025 Yes

Showing 5 of 1,480 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages